# IMCODE 001 (NCT03815058)

> A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03815058
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Genentech, Inc.
- Conditions: Advanced Melanoma
- Interventions: Autogene cevumeran; Pembrolizumab
- Enrollment: 131
- Primary outcome: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v.1.1) After Randomization

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=imcode-001-nct03815058